超11000家定点医药机构可买2025年医保目录新药

Core Insights - The National Healthcare Security Administration (NHSA) is facilitating the implementation of negotiated drugs in the 2025 medical insurance catalog, providing a list of new negotiated drugs and innovative commercial insurance drugs for 2025 [1][2] Group 1: New Drug Distribution - As of January 11, 2026, 105 new negotiated drugs have been included in the medical insurance catalog, distributed across 11,129 designated medical institutions nationwide [1] - Among the 105 new negotiated drugs, 88 have available distribution information, with two drugs, namely Increlex and Liposomal Irinotecan, available in all 31 provinces and the Xinjiang Production and Construction Corps [1] - 20 drugs are available in more than 30 provinces, 53 drugs in more than 20 provinces, and 67 drugs in more than 10 provinces [1] Group 2: Commercial Insurance Drugs - There are 19 innovative commercial insurance drugs, with 16 having distribution information, and the drug Ipilimumab is available in over 30 provinces [1] - Seven commercial insurance drugs are distributed in more than 20 provinces, and 12 drugs are available in more than 10 provinces [1] Group 3: Monitoring and Compliance - The NHSA will focus on monitoring drugs that have not yet been distributed to designated medical institutions, ensuring that companies comply with distribution requirements to protect the medication rights of insured individuals [2]